Results 51 to 60 of about 66,268 (303)

Gastrointestinal endogenous proteins as a source of bioactive peptides : Doctor of Philosophy in Nutritional Sciences at Riddet Institute, Massey University, Palmerston North, New Zealand [PDF]

, 2016
Gastrointestinal endogenous proteins (GEP) were investigated as a source of bioactive peptides. In silico and in vitro methods were used singly or in combination to study GEP-derived peptides after simulated digestion.
Acharya, Prasannalakshmi
core  

Seprase: An overview of an important matrix serine protease [PDF]

, 2008
Seprase or Fibroblast Activation Protein (FAP) is an integral membrane serine peptidase, which has been shown to have gelatinase activity. Seprase has a dual function in tumour progression.
Abbott, Abbott, Abbott, Acharya, Adams, Adams, Aertgeerts, Aimes, Alcolado, Aoyama, Ariga, Artym, Bangert, Barrett, Bauvois, Bermpohl, Birney, Bissell, Brendan F. O'Connor, Brown, Busek, Chen, Chen, Chen, Chen, Cheng, Cheng, Christiansen, Collins, Corpet, De Wever, Del Rosso, Dolznig, Dvorak, Edosada, Edosada, Fassnacht, Fidler, Fink, Flentke, Fulop, Garcia-Horsman, Garin-Chesa, Gerner, Ghersi, Ghersi, Ghersi, Gilmore, Goldstein, Goldstein, Goodman, Gorrell, Guex, Hofheinz, Huang, Huber, Huber, Ibrahim, Iwasa, Jin, Kelly, Kelly, Kelly, Kelly, Kloft, Koyama, Lee, Lee, Lee, Lee, Lee, Levy, Levy, Levy, Loeffler, Mathew, Mersmann, Milner, Monsky, Mori, Mueller, Nicholas, Niedermeyer, Niedermeyer, Niedermeyer, Oertel, Okada, Okada, Ollis, Pamela O'Brien, Park, Pineiro-Sanchez, Ramirez-Montagut, Rennex, Rettig, Rettig, Rettig, Rettig, Rosenblum, Samel, Scanlan, Schechter, Scott, Scott, Sieweke, Skubitz, Stremenova, Sun, Tahtis, Tran, Wang, Wang, Welt, Welt, Wesley, Zhang   +115 more
core   +1 more source

Identifying Cytokine Motif‐Containing, Immunomodulatory Bacterial Proteins in Human Gut Microbiome

Advanced Science, EarlyView.
By building and constructing HMM (Upper left, blue), the authors identify CMCPs in bacteria genomes and CRC related metagenomes and enriched CRC‐related CMCPs (Upper right, blue). They analyze sequence and structural similarity of hits (Lower left, green), test function with engineered EcN delivered to tumors in a mouse tumor model (Lower right, pink ...
Ziyu Wang, Siqi Guo, Jing Li, Qianqian Huang, Jing Ning, Binbin Xia, Xun Lv, Xiang Liu, Zeyu Gao, Jine Li, Longchao Liu, Moshi Song, Jun Wang   +12 more
wiley   +1 more source

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin [PDF]

Diabetes & Metabolism Journal, 2016
BackgroundWe compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes ...
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim   +16 more
doaj   +1 more source

Dipeptidyl Peptidase-4 Inhibitor

Korean Journal of Medicine, 2014
Recent advances in incretin biology have led to the development of a new class of oral anti-diabetic drugs. To date, there are two known incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), of which the former is a more important therapeutic target for type 2 diabetes.
openaire   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Cardioprotective effects of sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase 4 inhibitor in type 2 diabetes: A meta-analysis of comparative safety and efficacy

SAGE Open Medicine
Background: Sodium glucose cotransporter 2 inhibitors are recommended for the treatment of heart failure due to their cardioprotective effects, despite primarily being used as antidiabetic medications. However, the comparative profile of two antidiabetic
Abhigan Babu Shrestha, Anupam Halder, Kripa Rajak, Saroj Kumar Jha, Ramesh Lamichhane, Arefin Naher Oishee, Nayanika Tummala Chowdary, Pashupati Pokharel, Sajina Shrestha, Lukash Adhikari, Bikash Adhikari, Aman Rajak, Jalal Haider Khan, Nischal Mainali   +13 more
doaj   +1 more source

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions

Indian Journal of Endocrinology and Metabolism, 2014
The pharmacological actions of the glucagon-like peptide-1 receptor agonists (GLP-1RA) are largely predictable as they interact directly with GLP-1 receptors on beta cells to mediate their glucose lowering effects by increasing GLP-1 in pharmacological ...
Awadhesh Kumar Singh
doaj   +1 more source

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Diabetology & Metabolic Syndrome, 2021
Background Dipeptidyl peptidase 4 (DPP4) is a serine exopeptidase able to inactivate various oligopeptides, and also a hepatokine. Hepatocyte-specific overexpression of DPP4 is associated with hepatic insulin resistance and liver steatosis.
Sachiko Hattori, Kazuomi Nomoto, Tomohiko Suzuki, Seishu Hayashi   +3 more
doaj   +1 more source